Type 1 Diabetes TrialNet
Study Participants Healthcare Professionals Researchers Locations Publications What is TrialNet? News and Events Get Screened! Home

Information for Study Participants

CTLA-4 Ig (Abatacept) in Recent Onset Diabetes

Status: No Longer Recruiting

Study Findings

Abatacept helps slow progression of type 1 diabetes in newly diagnosed

In a two-year study, the drug abatacept was used to treat 112 people, ages 6-45, with newly diagnosed type 1 diabetes. Abatacept is used to treat several inflammatory conditions. Those in the treatment group experienced an average 9.6 month delay in progression of insulin loss. After two years of continued treatment, insulin production was 59% higher in those who received abatacept than those who received a placebo.

One year after treatment, the delay in insulin loss continued in the abatacept group. This is especially important because protecting one’s ability to make even small amounts of insulin means better glucose control and improved outcomes. Further trials will be needed to determine if a shorter course of abatacept might be sufficient in achieving similar beneficial effects.

Initial study results were presented at the American Diabetes Association (ADA) Scientific Sessions in San Diego in June 2011 and published in the June 27, 2011 edition of The Lancet. Follow-up results were reported at the ADA Scientific Sessions in Philadelphia in June 2012.

Read Full Study Description